Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Large Decline in Short Interest

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totalling 584,300 shares, a decline of 14.5% from the May 31st total of 683,200 shares. Based on an average trading volume of 565,000 shares, the short-interest ratio is presently 1.0 days. Currently, 3.5% of the company’s stock are short sold.

Theriva Biologics Stock Performance

NYSEAMERICAN:TOVX opened at $0.24 on Friday. The firm has a market capitalization of $4.08 million, a price-to-earnings ratio of -0.21 and a beta of 1.38. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.60 and a quick ratio of 3.60. Theriva Biologics has a 52 week low of $0.20 and a 52 week high of $1.01.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its earnings results on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.